Cutting-Edge Biotech Company
Redefines Healthcare
Chronic diseases affect over 2 billion people globally, being one of the largest threats to societies worldwide. If these diseases spiral out of control — a scenario the UN has been warning about since 1989 — it won’t just devastate the healthcare market; it will disrupt every market and impact us all.
Environmental factors and contaminated food promote processes like inflammation, exacerbating onset and progression of chronic diseases, leading to endothelial cell (the inner lining of blood vessels) damage and fibrosis (excessive connective tissue growth). Especially in the developed countries, the growing burden of chronic diseases is straining healthcare systems beyond their capacity.
The entire healthcare sector, including diagnostics and pharmaceuticals drugs, but also the food industry face nearly insurmountable challenges if the current situation remains unchanged — without understanding and exploiting the knowledge on the proteomic mechanisms underlying chronic diseases.
Until now, the complex molecular mechanisms behind chronic diseases, which develop silently and only become apparent after significant organ damage, were largely unknown.
Chronic diseases could only be detected based on irreversible organ damage, therapies were untargeted, too late and not taking the individual phenotype into account. This will now be changed: Mosaiques’ proprietary proteome analysis approach combined with a huge database and proprietary algorithms enables early disease detection, prior to irreversible organ damage, and guiding individualized therapy.
Mosaiques' proteome analysis uncovers the mechanisms of chronic diseases by identifying disease-specific proteome changes and defining biomarkers.
You can find more information about our business in our presentations, available in the download center.
Company overview
▶ Since 2002 - Headquarter: Hanover, Germany
▶ Industry: Biotechnology - Special feature "Proteome decoding" - Medicine B2C and B2B
▶ Unique position of mosaiques:
The molecular mechanism causing non-infectious diseases has been decoded by mosaiques' proprietary proteome analysis platform, connected to molecular pathophysiology, proven in highly qualified clinical studies with a special artificial intelligence (AI) and opening up the urgently needed major improvement in medicine. The proprietary knowledge on the proteome enables mapping disease with - environmental influence - food - drugs - and enables significant mutual gains in knowledge of a "perpetuum mobile", which the mosaiques proteome database extends to this unique highly qualified level. Mosaiques has also set extensive standards in the comprehensive scientific knowledge acquisition of the proteome.
▶ The medical/clinical benefits are:
- Diseases can be defined on the molecular level, recognized precisely and early - before organ damage - and treated in a targeted manner;
- Patients receive the optimal intervention, based on their specific disease proteome. Depending on the exact molecular cause of the disease, different proteins (and biomarkers) are affected. However, the approved drugs for the same underlying disease act on different targets, corresponding to different biomarkers, depending on the molecular disease signature. Now it is possible to link the specific disease biomarkers to the molecular impact of intervention, using the proteome analysis of mosaiques;
- Based on the extensive database drugs can be developed targeted, faster and at lower cost;
- Dietary and lifestyle changes can be suggested based on the specific, personalized proteome, to support pharmacological therapy.
▶ Market: 2 billion people
(In contrast: rare diseases due to genetic defects may account 10 million cases worldwide, detectable on the genome level)
Status quo
Chronic diseases develop without symptoms. They are triggered and driven by multiple specific changes in the proteome. Currently, these diseases are detected and treated based on substantial organ damage. However, drugs only act on proteins, they cannot revive dead cells or repair damaged organs. Cardiovascular and kidney diseases, and cancer in particular require over 50 % of the resources, costs and personnel in the healthcare system of developed countries.
Changes in this situation can be made with mosaiques!
For the first time, mosaiques' complex proteome biomarkers define the multiple disease-specific, molecular changes of chronic diseases. These diseases are the result of proteome changes, which are also responsible for the stage of the disease in its different manifestations. The in-vitro diagnostics for cardiovascular and kidney diseases as well as individual cancers have already been approved and are being marketed.
The comprehensive precision proteome biomarkers, depicting the molecular pathophysiology of the specific disease, reveal the molecular mechanism of disease at an individual level. They reflect the different causality and predict the effect of specific intervention. This is precision medicine qua personalized diagnostics through the proteome!
- Target-oriented identification of drug candidates: This revolutionizes drug development in particular; reduces development time and risks, as well as costs. In addition, the disease-specific human proteome can be “translated” into the mouse model, improving testing of drug candidates and minimizing development, consequently saving costs.
- Mosaiques is currently already developing a bladder cancer drugs on this basis
- In the food sector, the effect of olive oil on cardiovascular disease has been demonstrated!
Study evidence and publications since 2002
There are now over 100 clinical, evidence-based studies, conducted jointly with 1,200 renowned doctors and scientists worldwide from 85 university hospitals in over 400 publications, many funded by the EU Commission and published in leading scientific journals, clearly desmontrating clinical benefits in the respective indication (disease area).
Social impact
The UN has placed the threat to humanity posed by these chronic diseases on a par with Ebola. The growing demographic change poses the threat of the collapse of Western healthcare systems.
Diet (including contaminated food chains), environmental influences, lifestyle - everything has an effect on proteins. Knowledge of the proteome's mechanism of action will become the basis of human existence.
This paradigm shift through knowledge of the proteome will considerably relieve the impact of chronic disease and substantially improve cost- and personnel-intensive medicine, which is currently focused towards coping with organ damage and reducing the rate of progression.
Mosaiques’ method of proteome analysis = the basis of precision medicine!
PROTEOMICS knowledge of the molecular mechanism of diseases and specific biomarkers is revolutionizing all areas of knowledge for maintaining human health.
Until now, the specific mechanism of action of drugs in individual patients was generally unknown. Drugs have been developed and administered without knowledge of the complex proteomic changes. However, drugs only act on certain target proteins and therefore only on certain manifestations of the underlying disease, such as heart failure, which only affect some patients. Other drugs act on other target proteins of the same disease, which, however, has a further causality. So far, it has not been possible to target molecular therapy settings or to develop an active substance for the previously unknown complex disease-specific proteome biomarkers. Without knowledge of the proteome, drugs at best only demonstrated a benefit in 15 - 30 % of patients. The chronic diseases diagnosed based on organ damage could not be cured, for a minority the dynamic progression of the disease could be attenuated. By means of mosaiques' proteome analysis, the chronic disease is detected even before organ damage, and the patient receives precisely targeted treatment, ideally preventing organ damage.
Unique database and AI
The unique, highly qualified, proprietary proteome database including patients history and anamnesis is built on over 100 clinical studies with over 85,000 patients and their disease progression with millions of individual protein assessments. In addition to this unique database, the validity and robustness of the applied technology forms the basis for the identification of biomarkers for other indications, which also take place in collaborations - B2B - (see: www.power-of-proteomics.com). The high quality and patient benefit of the proteome data has been demonstrated in evidence-based studies for every indication. According to our research, no protein method has yet been able to demonstrate such patient benefit - B2C.
The proteome (totality of all proteins) is analysed from body fluids, primarily from urine, the "filtrate of the blood", and compared with the disease proteome specifically validated in studies using AI on the basis of mosaiques' extensive proteome database. The findings are displayed as a psequdo 3D data sheet. Diagnosis and personalized therapy is based on this individual proteome.
If you are interested in innovations to tackle the massive, dynamically growing health problems of developed countries and want to get involved, then register to access the password-protected page*:
*You will receive the password by contacting us via the contact form.
Joachim Conrads
Joachim Conrads is the founder and legal advisor of mosaiques diagnostics and therapeutics AG (MDAG). He has studied law and philosophy and is an internationally active investor. His achievements were honored with the “Golden Nose” award for the Business Angel of the Year 2002. He has long-standing expertise in law, IPR, finances, as well as marketing.
Prof. Dr. Dr. Harald Mischak
Professor Harald Mischak is co-founder of Mosaiques diagnostics and therapeutics AG (2002), which was started with the aim to identify disease-specific peptides. With more than 400 scientific publications on signaling and proteomics that have been cited over 37000 times (h-index in Google 106), he is one of the leading experts worldwide in the field of proteome research, personalized medicine, and applied systems biology.
